吉林敖东药业集团股份有限公司 2020 年第三季度报告全文 吉林敖东药业集团股份有限公司 2020 年第三季度报告 2020 年 10 月 1 吉林敖东药业集团股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李秀林、主管会计工作负责人张淑媛及会计机构负责人(会计主 管人员)李强声明：保证季度报告中财务报表的真实、准确、完整。 2 吉林敖东药业集团股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | |-----------------------------------------------------|-----------------------|---------------------------------------- ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 1,121,445,607.54, a decrease of 31.73% compared to CNY 1,642,579,794.10 in the same period last year[9]. - Net profit attributable to shareholders was CNY 1,020,099,858.24, an increase of 16.97% from CNY 872,113,433.98 year-on-year[10]. - The net profit after deducting non-recurring gains and losses reached CNY 1,044,491,211.06, reflecting a growth of 26.94% compared to CNY 822,844,295.99 in the previous year[10]. - The net cash flow from operating activities was CNY 336,388,321.86, showing a significant increase of 190.08% from CNY 115,962,509.53 in the same period last year[10]. - Basic earnings per share were CNY 0.88, up 17.33% from CNY 0.75 in the previous year[10]. - Total profit increased to CNY 10,242.79 million, an increase of CNY 1,072.35 million or 11.69% year-on-year[23]. - The company reported a total profit of CNY 1,024,278,617.81, up from CNY 917,043,908.38, indicating a growth of 11.7%[117]. - The total comprehensive income for the first half of 2020 was approximately CNY 1.19 billion, compared to CNY 841.18 million in the same period of 2019, representing an increase of about 41%[120]. Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 27,064,353,195.25, an increase of 4.90% from CNY 25,800,904,916.27 at the end of the previous year[10]. - The company's total assets increased to approximately 27.06 billion yuan from 25.80 billion yuan at the end of the previous year[111]. - Total liabilities reached CNY 3,964,628,585.52, up from CNY 3,356,209,814.31, reflecting a growth of approximately 18.1%[112]. - The company's equity attributable to shareholders increased to CNY 22,909,857,193.45 from CNY 22,249,498,565.07, a rise of about 3.0%[112]. - The total liabilities to equity ratio was approximately 0.17, indicating a stable leverage position[112]. Investment and Capital Management - The company plans to invest CNY 2.2 billion in securities management to enhance asset efficiency and returns[26]. - The company completed a significant equity investment in Guangfa Securities Co., Ltd. amounting to ¥195,445,670.77, acquiring a 0.34% stake[41]. - The company has allocated CNY 509.75 million of unutilized raised funds for working capital, optimizing its industrial layout[32]. - The company has invested CNY 2,084,200,000.00 in bonds, with a sale amount of CNY 2,054,282,370.35 during the reporting period[45]. - The company used 99,600 million yuan of the raised funds to increase capital in its subsidiaries to enhance profitability[95]. Research and Development - Research and development expenses decreased by 46.54% to CNY 45,545,535.47 from CNY 85,196,186.50 in the previous year, mainly due to reduced R&D spending by subsidiaries[33]. - The company plans to increase investment in new product research and development to mitigate the impact of national medical reform policies[52]. Market and Operational Challenges - The company faced operational challenges in the first half of 2020 due to the COVID-19 pandemic, impacting production and logistics[22]. - The company experienced a decrease in revenue across all major regions, with the Northeast region declining by 28.30% to CNY 309,859,964.06[34]. Shareholder and Equity Management - The company plans not to distribute cash dividends or issue bonus shares[2]. - The company has implemented an employee stock ownership plan, with 19,809,743 shares transferred to the plan's account[58]. - The total number of ordinary shareholders at the end of the reporting period was 93,172[80]. - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., held 26.65% of the shares, totaling 309,940,049 shares[80]. Environmental and Social Responsibility - The company has invested over 60 million yuan in wastewater treatment facilities over the past three years, with a maximum daily treatment capacity of 8,000 tons[68]. - The company is committed to poverty alleviation efforts, focusing on precise identification and management of poverty alleviation initiatives[69]. - A total of CNY 160.42 million was allocated for poverty alleviation efforts, benefiting 670 registered impoverished individuals[72]. Financial Reporting and Compliance - The company's financial statements are prepared based on the going concern principle and comply with relevant accounting standards[138]. - The company has no significant issues regarding its ability to continue as a going concern for the next 12 months[139]. - The company’s long-term credit rating remains at AA+ with a stable outlook, as confirmed by Pengyuan Credit Rating Co., Ltd. in multiple reports from 2017 to 2020[99][100].

证券代码：000623 证券简称：吉林敖东 公告编号：2020-081 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，吉林敖东药业集团股份有限公司（以下 简称"公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限 公司共同举办的"提高公司质量 做受尊敬的上市公司--2020 年吉林辖区上市公 司投资者网上集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景·路演天下"网站（http://rs.p5w.net）参与公司 本次投资者集体接待日活动,时间为 2020 年 8 月 21 日（周五）15:30 至 17:00。 届时公司副董事长、总经理郭淑芹女士，副总经理、财务总监张淑媛女士及 董事会秘书王振宇先生将通过网络在线问答互动的形式，与投资者就公司治理、 发展经营情况、融资情况和可持续发展等投资者关注的问题进行交流。期间，公 ...

吉林敖东药业集团股份有限公司 2020 年第一季度报告全文 吉林敖东药业集团股份有限公司 2020 年第一季度报告 2020 年 04 月 吉林敖东药业集团股份有限公司 2020 年第一季度报告全文 1 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李秀林、主管会计工作负责人张淑媛及会计机构负责人(会计主 管人员)李强声明：保证季度报告中财务报表的真实、准确、完整。 吉林敖东药业集团股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | |-----------------------------------------------------------|-------------------|-------|-------------------|----------- ...

Financial Performance - The company's operating revenue for 2019 was ¥3,088,379,591.97, a decrease of 7.09% compared to ¥3,324,078,265.78 in 2018[8]. - Net profit attributable to shareholders for 2019 was ¥1,403,640,313.56, representing a 50.09% increase from ¥935,187,893.18 in 2018[8]. - The net profit after deducting non-recurring gains and losses was ¥1,277,462,446.54, up 45.43% from ¥878,430,261.44 in the previous year[8]. - Basic earnings per share for 2019 were ¥1.2070, an increase of 50.07% compared to ¥0.8043 in 2018[8]. - The total operating revenue for the company in 2019 was RMB 3,088,379,591.97, representing a decrease of 7.09% compared to RMB 3,324,078,265.78 in 2018[34]. - The net profit attributable to shareholders was CNY 140,364.03 million, an increase of CNY 46,845.24 million or 50.09% year-on-year[22]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2019, representing a year-over-year increase of 10%[147]. - The net profit for the year was 300 million RMB, which is a 15% increase compared to the previous year[147]. Assets and Liabilities - Total assets at the end of 2019 were ¥25,800,904,916.27, a 4.63% increase from ¥24,658,542,292.54 at the end of 2018[8]. - Net assets attributable to shareholders at the end of 2019 were ¥22,249,498,565.07, reflecting a 5.81% increase from ¥21,028,405,792.95 in 2018[8]. - The total assets of the company at the end of 2019 were ¥25.80 billion, with net assets of ¥22.44 billion[15]. - The asset-liability ratio stands at 13.01%, indicating a strong financial position[22]. - The company's total assets-liabilities ratio as of December 31, 2019, was 13.01%, a decrease from 13.85% in 2018, indicating strong debt repayment capability[181]. Cash Flow - The company reported a net cash flow from operating activities of ¥379,456,901.57, an increase of 9.15% from ¥347,635,221.58 in 2018[8]. - The total cash inflow from operating activities in 2019 was CNY 3,521,658,072.52, a decrease of 4.53% compared to 2018[5]. - The net cash flow from investment activities turned positive at CNY 157,887,970.79, a 109.00% increase compared to the previous year[5]. - Cash and cash equivalents increased by CNY 275,722,053.55, a decrease of 62.04% year-on-year[5]. Investments and Acquisitions - The company invested CNY 8,244.17 million in the automation production line project, which has commenced production[25]. - The company completed the acquisition of Auscon Biopharmaceuticals with an investment of CNY 12 million, holding a 1.39% stake[52]. - The company invested CNY 152.47 million in various self-built projects, with a cumulative actual investment of CNY 259.17 million by the end of the reporting period[53]. - The company plans to invest 100 million yuan in R&D for new technologies over the next two years[140]. Research and Development - R&D efforts include the development of new drugs and classic formulas, with ongoing projects for various treatments including pancreatic and lung cancer[26]. - Research and development expenses rose by 62.52% to 142,897,914.24 yuan, primarily due to increased product development spending by subsidiaries[43]. - The company aims to enhance its core competitiveness through continuous investment in talent development and training programs[32]. Market and Sales - The pharmaceutical segment generated RMB 2,897,045,013.07, accounting for 93.80% of total revenue, with an 8.61% decline from RMB 3,170,006,912.71 in the previous year[34]. - The food segment revenue increased by 31.76% to RMB 131,045,206.69, compared to RMB 99,460,290.59 in 2018[34]. - The total sales volume for the pharmaceutical sector decreased by 1.86% to 106,696,920 boxes in 2019 compared to 2018[36]. - The production volume for food increased by 57.70% to 11,382,853 boxes in 2019, driven by the growth of the subsidiary Jilin Aodong Health Technology Co., Ltd.[36]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of ¥2 per 10 shares to all shareholders[2]. - The total cash dividend amount for 2019 is 232,607,090.80 CNY, which represents 16.57% of the net profit attributable to ordinary shareholders[83]. - The cash dividend total for 2019 represents 100% of the total distributable profits[85]. Corporate Governance - The company has established a robust investor relations management system to enhance communication with investors[157]. - The company operates independently from its controlling shareholder in business, personnel, assets, institutions, and finance[159]. - The company’s board of directors is responsible for establishing and maintaining effective internal controls as per regulatory requirements[172]. Environmental and Social Responsibility - The company has invested over 60 million RMB in wastewater treatment facilities over the past three years, achieving a maximum daily treatment capacity of 8,000 tons[110]. - The company has actively integrated ecological and environmental protection requirements into its development strategy and governance processes[110]. - A total of 28 million yuan was allocated for poverty alleviation efforts, helping 225 registered impoverished individuals to escape poverty[106]. Future Outlook - The company provided a future outlook, projecting a revenue growth of 10% for the next fiscal year[136]. - The company has set a revenue guidance of 1.8 billion RMB for the fiscal year 2020, projecting a growth of 20%[147]. - The company plans to enhance its digital marketing efforts, aiming for a 30% increase in online sales channels[147].

Financial Performance - Operating revenue decreased by 12.27% to CNY 715,984,530.35 compared to the same period last year[3] - Net profit attributable to shareholders decreased slightly by 0.02% to CNY 287,593,890.59 compared to the same period last year[3] - Net profit after deducting non-recurring gains and losses increased by 4.20% to CNY 280,901,534.93 compared to the same period last year[3] - Basic earnings per share decreased by 0.04% to CNY 0.2473 compared to the same period last year[3] - Diluted earnings per share increased by 0.04% to CNY 0.2465 compared to the same period last year[3] - The weighted average return on equity was 1.33%, a decrease of 0.05% compared to the same period last year[3] - The total comprehensive income for the third quarter was CNY 288,216,002.04, down from CNY 350,046,111.19 in the same period last year, indicating a decline of 17.7%[26] - The net profit for the third quarter was CNY 284,540,757.67, slightly up from CNY 282,995,744.96 in the same period last year, reflecting a growth of 0.5%[26] - The total profit for the third quarter was CNY 301,054,120.13, slightly up from CNY 299,502,704.47 in the previous year, indicating a growth of 0.5%[26] Assets and Liabilities - Total assets increased by 4.14% to CNY 25,679,514,163.64 compared to the end of the previous year[3] - Total liabilities decreased to CNY 3,370,375,690.25 from CNY 3,414,160,963.84, showing a reduction of about 1.28%[19] - The company's total current assets reached CNY 6,152,836,061.00, up from CNY 5,801,997,576.69 in December 2018, indicating an increase of about 6.05%[17] - The total equity of the company increased to CNY 20,910,565,731.18 from CNY 20,104,377,556.79, reflecting a growth of approximately 4.0%[24] - The company's total liabilities reached CNY 2,084,332,917.57, compared to CNY 1,991,597,896.24, representing an increase of about 4.66%[22] - The total owner's equity reached CNY 22,309,138,473.39, up from CNY 21,244,381,328.70, indicating an increase of approximately 4.99%[19] Cash Flow - Cash flow from operating activities decreased by 40.22% to CNY 188,502,033.41 compared to the same period last year[3] - The ending balance of cash and cash equivalents was 1,896,676,761.32, down from 2,024,209,120.45 in the previous period, reflecting a decrease of about 6.3%[37] - Cash inflow from operating activities totaled 2,579,117,457.22, down from 2,676,860,371.64, marking a decline of approximately 3.6%[36] - Operating cash flow for the period was 188,502,033.41, a decrease from 315,302,865.68 in the previous period, indicating a decline of approximately 40.2%[36] Research and Development - The company's R&D expenses increased by 83.17% year-on-year to ¥110,694,497.61, primarily due to increased product development expenditures by subsidiaries[9] - Research and development expenses rose significantly to CNY 40,100,622.46, compared to CNY 12,458,801.49, marking an increase of about 221.5%[25] - The research and development expenses increased to CNY 110,694,497.61 from CNY 60,432,758.81 in the previous year, reflecting a significant increase of 83.2%[29] Investment Income - Investment income rose by 34.95% year-on-year to ¥941,623,783.47, attributed to higher returns from investments in Guangfa Securities Co., Ltd.[9] - The company reported a net investment income increase to CNY 247,591,555.11, up from CNY 216,482,214.48, which is an increase of approximately 14.4%[25] - The company’s investment income from joint ventures and associates increased to ¥933,216,241.86 from ¥669,764,566.38, reflecting a growth of about 39.4%[30] Other Comprehensive Income - The company's other comprehensive income after tax increased by 176.33% to ¥135,130,886.22, driven by increased other comprehensive income from Guangfa Securities[8] - Other comprehensive income after tax for the current period was ¥135,130,886.22, a recovery from a loss of ¥177,026,979.30 in the previous period[30] - The company reported a decrease in other comprehensive income by CNY 135,967,126.33 compared to the previous period[48] Shareholder Information - The company extended the employee stock ownership plan by 18 months, now set to expire on December 8, 2020[13] - The company committed to not trading or transferring shares for 36 months post the stock reform, with a maximum annual reduction of 2% of total shares at a minimum price of 7.5 yuan per share[14] - The company’s major shareholder's restricted shares will be fully tradable by August 4, 2020[14] Financial Standards - The company has implemented new financial instrument standards effective from January 1, 2019, impacting the classification and measurement of financial instruments[44] - The company implemented new financial instrument standards starting January 1, 2019, affecting the classification and measurement of financial instruments[49]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 1,642,579,794.10, representing a 3.93% increase compared to CNY 1,580,502,489.40 in the same period last year[9]. - Net profit attributable to shareholders was CNY 872,113,433.98, a 43.38% increase from CNY 608,241,663.21 year-on-year[10]. - The net profit after deducting non-recurring gains and losses was CNY 822,844,295.99, up 35.37% from CNY 607,836,792.61 in the previous year[10]. - Basic earnings per share increased to CNY 0.75, a rise of 44.23% compared to CNY 0.52 in the same period last year[10]. - The gross profit margin was 70.87%, a decrease of 1.17% compared to the same period last year[30]. - The pharmaceutical segment generated revenue of RMB 1,553,790,258.75, with a gross margin of 74.11%[30]. - The company reported a total of CNY 1,109,616,361.43 in securities investments, with a year-end book value of CNY 1,106,543,443.25[38]. - The company reported a total comprehensive income of CNY -238,858,399.35 for the current period, with a profit distribution of CNY -348,830,988.60[115]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 25,452,780,371.52, reflecting a 3.22% increase from CNY 24,658,542,292.54 at the end of the previous year[10]. - The net assets attributable to shareholders reached CNY 21,812,001,031.40, which is a 3.73% increase from CNY 21,028,405,792.95 at the end of the previous year[10]. - The company's total liabilities were CNY 3,430,406,105.67, slightly up from CNY 3,414,160,963.84, showing a marginal increase of about 0.5%[93]. - The total liabilities to equity ratio was approximately 15.7%, indicating a stable leverage position for the company[93]. - The company's long-term equity investments increased to CNY 15,966,996,324.35, representing 62.73% of total assets[32]. Cash Flow - The net cash flow from operating activities was CNY 115,962,509.53, down 38.44% from CNY 188,370,631.11 in the same period last year[10]. - The company’s operating cash flow decreased by 38.44% to 115.9625 million RMB due to increased operating expenses[29]. - The cash inflow from investment activities reached ¥2,091,472,158.13, significantly up from ¥413,566,231.73 in the first half of 2018[106]. - The cash and cash equivalents at the end of the first half of 2019 amounted to 1,939,800,326.10, compared to 1,427,518,742.77 at the end of the first half of 2018[105]. Investments and R&D - Research and development investment increased by 24.19% to 85.1962 million RMB compared to the previous year[29]. - The company has invested 100 million RMB in research and development for innovative technologies to improve production efficiency[128]. - The company reported investment income of CNY 694,032,228.36, which is an increase from CNY 481,277,265.08 in the first half of 2018[99]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[2]. - The company is focusing on innovation and quality improvement to adapt to the evolving pharmaceutical industry landscape[20]. - The company has established a dual-driven growth model of "industry + finance" to support its development strategy[19]. - The company plans to enhance product quality and service levels while accelerating new product development to adapt to ongoing pharmaceutical policy changes[43]. Market and Competition - The company is expanding its market presence by entering two new regions, which is anticipated to increase market share by 5%[128]. - A strategic acquisition of a smaller competitor was completed, valued at 500 million RMB, aimed at enhancing product offerings and market reach[128]. Shareholder Information - The total number of shares held under the employee stock ownership plan is 25,752,666 shares, with 86.08% held by employees and the remaining by directors and supervisors[53]. - The company plans to increase its stake in Jilin Aodong Pharmaceutical Group by at least 5% within 12 months after the implementation of the share reform plan, aiming for a total holding of 25% within 36 months[48]. - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., held 26.65% of shares, totaling 309,940,049 shares[74]. Environmental and Social Responsibility - The company actively participates in precision poverty alleviation efforts, focusing on targeted support and resource allocation[66]. - The company signed a poverty alleviation cooperation agreement for black bean planting with the Xiaowazi Village, contributing to local economic development[67]. - The company has implemented effective pollution prevention measures, ensuring that emissions meet environmental standards[64]. Financial Management - The company has a total bank credit line of 3.1 billion CNY, with an unused portion of 3.1 billion CNY as of June 30, 2019[89]. - The company maintained a 100% loan repayment rate and interest payment rate during the reporting period[87]. - The company has adhered to the commitments outlined in the convertible bond prospectus without harming investor interests[90]. Risk Factors - The company is facing risks from increasing environmental regulations, which may lead to higher operational costs and potential production disruptions[44]. - The company’s product "Injection of Ribonucleic Acid II" has been included in the first batch of key monitored drug lists, which may adversely affect the company's performance[45].

Financial Performance - The company's operating revenue for Q1 2019 was ¥822,313,750.58, representing a 16.17% increase compared to ¥707,844,757.10 in the same period last year[2]. - The net profit attributable to shareholders was ¥644,704,659.65, a significant increase of 98.53% from ¥324,731,039.98 year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥512,113,548.03, up 64.23% from ¥311,824,397.38 in the previous year[2]. - The basic earnings per share increased to ¥0.55, reflecting a growth of 96.43% compared to ¥0.28 in the same period last year[2]. - The company reported a significant increase in management expenses by 57.17% to CNY 78.47 million, mainly due to higher personnel costs[8]. - The company reported a total comprehensive income of 670,173,222.41 yuan, compared to 146,464,293.00 yuan in the previous year, marking an increase of 356.5%[30]. Assets and Liabilities - The total assets at the end of the reporting period were ¥25,515,200,212.33, an increase of 3.47% from ¥24,658,542,292.54 at the end of the previous year[2]. - The total liabilities of the company were CNY 3.47 billion, slightly up from CNY 3.41 billion, which is an increase of around 1.73%[20]. - The equity attributable to shareholders of the parent company reached CNY 21.83 billion, compared to CNY 21.03 billion at the end of 2018, showing a growth of approximately 3.83%[20]. - The company's current assets totaled CNY 6.53 billion, up from CNY 5.80 billion at the end of 2018, indicating a growth of about 12.66%[18]. - The total amount of other receivables increased by 39.42% to CNY 40.68 million, attributed to accrued interest on time deposits and increased business receivables[8]. Cash Flow - The net cash flow from operating activities was negative at -¥18,114,196.77, a decline of 165.27% compared to ¥27,754,749.10 in the same period last year[2]. - The company's cash flow from operating activities showed a net outflow of CNY 18.11 million, a decrease of 165.27% compared to the previous year[9]. - Cash flow from investing activities showed a net inflow of 62,458,538.60 yuan, compared to 6,302,574.39 yuan in the previous year, indicating a significant increase[32]. - The total cash outflow from financing activities was CNY 4,825,511.20, compared to an inflow of CNY 2,390,158,700.00 in the previous period[33]. Investments - Investment income rose by 88.86% to CNY 495.48 million, primarily due to increased returns from investments in Guangfa Securities[8]. - The company has a total investment in securities amounting to approximately 1.05 billion CNY, with a fair value change profit of about 147.64 million CNY during the reporting period[16]. - The company reported investment income of ¥495,484,578.91, which is a substantial increase from ¥262,352,175.64 in the previous period[26]. Research and Development - Research and development expenses increased by 548.06% to CNY 46.47 million, reflecting a significant investment in product development[8]. - Research and development expenses for the current period are ¥46,471,477.59, a significant increase from ¥7,170,898.54 in the previous period, indicating a focus on innovation[26]. Shareholder Information - The top shareholder, Dunhua Jincheng Industrial Co., Ltd., holds 26.66% of the shares, amounting to 309,940,049 shares, with a significant portion pledged[5]. - The major shareholder, Jincheng Company, committed to not selling more than 2% of the total shares of Jilin Aodong per year after the lock-up period[14]. - The employee stock ownership plan has a lock-up period of 36 months, with a minimum selling price of 32 CNY per share after the lock-up period ends[13]. Miscellaneous - The company did not conduct any repurchase transactions during the reporting period[7]. - The company anticipates significant fluctuations in net profit compared to the same period last year[15]. - The first quarter report was not audited, indicating that the financial data may be subject to further review[39].

Financial Performance - The company's operating revenue for 2018 was CNY 3,324,078,265.78, representing an increase of 11.67% compared to CNY 2,976,771,644.51 in 2017[21] - The net profit attributable to shareholders for 2018 was CNY 935,187,893.18, a decrease of 49.81% from CNY 1,863,471,361.46 in 2017[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 878,430,261.44, down 48.57% from CNY 1,708,064,399.15 in the previous year[21] - The basic earnings per share for 2018 was CNY 0.8043, a decline of 49.81% compared to CNY 1.6026 in 2017[21] - The total assets at the end of 2018 were CNY 24,658,542,292.54, an increase of 12.95% from CNY 21,831,626,601.10 at the end of 2017[21] - The net assets attributable to shareholders at the end of 2018 were CNY 21,028,405,792.95, up 3.71% from CNY 20,276,757,145.38 at the end of 2017[21] - The net cash flow from operating activities for 2018 was CNY 347,635,221.58, an increase of 35.54% from CNY 256,485,969.89 in 2017[21] - The weighted average return on net assets for 2018 was 4.51%, down from 9.59% in 2017, a decrease of 5.08%[21] Revenue Breakdown - In 2018, the company's total revenue for the fourth quarter reached ¥927,430,025.15, with a total annual revenue of ¥3,304,078,236.78[25] - The net profit attributable to shareholders for the fourth quarter was ¥39,303,373.20, while the annual net profit was ¥1,025,187,633.18, reflecting a year-on-year increase of 5.2%[25] - The pharmaceutical segment revenue was ¥3,170,006,912.71, accounting for 95.36% of total revenue, with a year-on-year growth of 9.76%[65] - The food segment saw a significant increase in revenue to ¥99,460,290.59, up 55.54% from ¥63,947,031.97 in 2017[65] - Total revenue for the pharmaceutical and food sectors reached ¥924,894,551.98, reflecting a year-on-year increase of 7.12%[73] Investments and Acquisitions - The company issued CNY 2,413 million in convertible bonds, raising a net amount of CNY 2,388.54 million for business expansion[42] - The company completed the acquisition of 100% equity in Aodong Pharmacy, increasing its registered capital to CNY 200 million, aimed at expanding retail pharmacy outlets[56] - The company invested CNY 80 million to establish Jilin Boya Special Medical Nutrition Technology Co., Ltd., focusing on special medical purpose formula foods[57] - The company invested CNY 3.335 billion in the non-public issuance of A-shares of GF Securities, holding a total of 17.45% of GF Securities' equity[55] - The company has invested CNY 599.33 million in the construction of an intelligent factory for traditional Chinese medicine[46] Research and Development - The company increased its investment in research and development, with R&D expenses amounting to ¥87,923,838.29, a decrease of 4.20% compared to the previous year[82] - The number of R&D personnel increased to 242 in 2018, up 35.96% from 178 in 2017, with R&D personnel accounting for 6.36% of total employees[85] - R&D investment amounted to ¥123,671,942.05 in 2018, representing a 31.38% increase from ¥94,130,909.05 in 2017, with R&D investment as a percentage of operating revenue rising to 3.72%[85] - The amount of capitalized R&D investment surged by 1,070.81% to ¥35,748,103.76, indicating a significant increase in investment in traditional Chinese medicine research[88] Dividend Policy - The company plans to distribute a cash dividend of CNY 2 per 10 shares to all shareholders, with no bonus shares issued[5] - The company's ordinary share cash dividend for 2018 was 232,556,500.20 CNY, representing 24.87% of the net profit attributable to ordinary shareholders in the consolidated financial statements[148] - The cash dividend policy for 2018 proposed a distribution of 2.00 CNY per 10 shares, with no stock bonus or capital reserve transfer[148] - The company has maintained a consistent cash dividend payout ratio over the past three years, with 2016, 2017, and 2018 ratios at 16.10%, 18.72%, and 24.87% respectively[148] Operational Challenges and Risks - The company faces risks from regulatory changes in the pharmaceutical industry, which may impact R&D and production quality[134] - Environmental regulations are becoming stricter, potentially increasing the company's operational costs related to compliance[134] - Price reforms in the pharmaceutical sector may adversely affect the company's operating performance if drug prices fluctuate significantly[134] - The company is exposed to risks related to product quality issues due to potential uncontrollable factors, despite strict adherence to GMP standards[137] - The market for raw materials is experiencing price increases due to environmental evaluations and labor costs, leading to potential monopolistic risks[137] Corporate Social Responsibility - The company actively fulfills its social responsibilities, integrating them into its strategic development[198] - The company has implemented targeted poverty alleviation measures, including a medicinal black bean planting project that generated a revenue of 100,000 yuan[200] - The company donated 2 million yuan to the "Taonan City Poverty Alleviation Photovoltaic Power Station" project[200] - The company prioritizes hiring impoverished laborers in its projects to support local economic development[200]

吉林敖东药业集团股份有限公司 2018 年第三季度报告正文 | 证券代码：000623 | 证券简称：吉林敖东 | 公告编号：2018-078 | | --- | --- | --- | | 债券代码：127006 | 债券简称：敖东转债 | | 吉林敖东药业集团股份有限公司 2018 年第三季度报告正文 1 吉林敖东药业集团股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李秀林、主管会计工作负责人张淑媛及会计机构负责人(会计主 管人员)李强声明：保证季度报告中财务报表的真实、准确、完整。 2 吉林敖东药业集团股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- ...